Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival

Giora M. Mavligit, Jordan U. Gutterman, Mary Anne Malahy, Michael A. Burgess, Charles M. McBride, Andre Jubert, Evan M Hersh

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The poor postsurgical prognosis in patients with colorectal cancer of the Dukes' C classification has prompted a clinical trial of adjuvant immunotherapy versus chemoimmunotherapy intended to prolong either the disease‐free interval or the overall survival or both. One hundred and twenty‐one patients have been entered on this study. Fifty‐two patients received BCG alone and 69 patients received the combination of 5‐FU and BCG. The disease‐free interval and the overall survival were compared with similar parameters in a group of historical controls with similar prognostic characteristics who were operated on in our institution prior to the initiation of the current study. There was no difference as yet between BCG alone and the combination of 5‐FU + BCG in terms of both the disease‐free interval and the survival. Both treatments, however, had significantly better results than the surgical controls. Adjuvant therapy, especially with BCG is advocated for patients with colorectal carcinoma, Dukes' C class, following potentially curative surgery.

Original languageEnglish (US)
Pages (from-to)2726-2730
Number of pages5
JournalCancer
Volume40
Issue number5 S
DOIs
StatePublished - 1977
Externally publishedYes

Fingerprint

Mycobacterium bovis
Immunotherapy
Colorectal Neoplasms
Survival
Fluorouracil
Clinical Trials
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival. / Mavligit, Giora M.; Gutterman, Jordan U.; Malahy, Mary Anne; Burgess, Michael A.; McBride, Charles M.; Jubert, Andre; Hersh, Evan M.

In: Cancer, Vol. 40, No. 5 S, 1977, p. 2726-2730.

Research output: Contribution to journalArticle

Mavligit, Giora M. ; Gutterman, Jordan U. ; Malahy, Mary Anne ; Burgess, Michael A. ; McBride, Charles M. ; Jubert, Andre ; Hersh, Evan M. / Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival. In: Cancer. 1977 ; Vol. 40, No. 5 S. pp. 2726-2730.
@article{5bfc1561abc34d91b8f8f8aacf95cecb,
title = "Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival",
abstract = "The poor postsurgical prognosis in patients with colorectal cancer of the Dukes' C classification has prompted a clinical trial of adjuvant immunotherapy versus chemoimmunotherapy intended to prolong either the disease‐free interval or the overall survival or both. One hundred and twenty‐one patients have been entered on this study. Fifty‐two patients received BCG alone and 69 patients received the combination of 5‐FU and BCG. The disease‐free interval and the overall survival were compared with similar parameters in a group of historical controls with similar prognostic characteristics who were operated on in our institution prior to the initiation of the current study. There was no difference as yet between BCG alone and the combination of 5‐FU + BCG in terms of both the disease‐free interval and the survival. Both treatments, however, had significantly better results than the surgical controls. Adjuvant therapy, especially with BCG is advocated for patients with colorectal carcinoma, Dukes' C class, following potentially curative surgery.",
author = "Mavligit, {Giora M.} and Gutterman, {Jordan U.} and Malahy, {Mary Anne} and Burgess, {Michael A.} and McBride, {Charles M.} and Andre Jubert and Hersh, {Evan M}",
year = "1977",
doi = "10.1002/1097-0142(197711)40:5+<2726::AID-CNCR2820400947>3.0.CO;2-L",
language = "English (US)",
volume = "40",
pages = "2726--2730",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5 S",

}

TY - JOUR

T1 - Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival

AU - Mavligit, Giora M.

AU - Gutterman, Jordan U.

AU - Malahy, Mary Anne

AU - Burgess, Michael A.

AU - McBride, Charles M.

AU - Jubert, Andre

AU - Hersh, Evan M

PY - 1977

Y1 - 1977

N2 - The poor postsurgical prognosis in patients with colorectal cancer of the Dukes' C classification has prompted a clinical trial of adjuvant immunotherapy versus chemoimmunotherapy intended to prolong either the disease‐free interval or the overall survival or both. One hundred and twenty‐one patients have been entered on this study. Fifty‐two patients received BCG alone and 69 patients received the combination of 5‐FU and BCG. The disease‐free interval and the overall survival were compared with similar parameters in a group of historical controls with similar prognostic characteristics who were operated on in our institution prior to the initiation of the current study. There was no difference as yet between BCG alone and the combination of 5‐FU + BCG in terms of both the disease‐free interval and the survival. Both treatments, however, had significantly better results than the surgical controls. Adjuvant therapy, especially with BCG is advocated for patients with colorectal carcinoma, Dukes' C class, following potentially curative surgery.

AB - The poor postsurgical prognosis in patients with colorectal cancer of the Dukes' C classification has prompted a clinical trial of adjuvant immunotherapy versus chemoimmunotherapy intended to prolong either the disease‐free interval or the overall survival or both. One hundred and twenty‐one patients have been entered on this study. Fifty‐two patients received BCG alone and 69 patients received the combination of 5‐FU and BCG. The disease‐free interval and the overall survival were compared with similar parameters in a group of historical controls with similar prognostic characteristics who were operated on in our institution prior to the initiation of the current study. There was no difference as yet between BCG alone and the combination of 5‐FU + BCG in terms of both the disease‐free interval and the survival. Both treatments, however, had significantly better results than the surgical controls. Adjuvant therapy, especially with BCG is advocated for patients with colorectal carcinoma, Dukes' C class, following potentially curative surgery.

UR - http://www.scopus.com/inward/record.url?scp=0017625271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017625271&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197711)40:5+<2726::AID-CNCR2820400947>3.0.CO;2-L

DO - 10.1002/1097-0142(197711)40:5+<2726::AID-CNCR2820400947>3.0.CO;2-L

M3 - Article

C2 - 922710

AN - SCOPUS:0017625271

VL - 40

SP - 2726

EP - 2730

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5 S

ER -